Journal
TRENDS IN BIOTECHNOLOGY
Volume 32, Issue 9, Pages 456-465Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2014.06.007
Keywords
artificial antigen-presenting cell; synthetic dendritic cell; immunotherapy; cancer
Categories
Funding
- EU (ERC advanced PATHFINDER) [269019]
- Dutch Cancer Society [KUN2009-4402]
- Netherlands Organization for Scientific Research (NWO) (Veni) [86313024]
- Dutch government [FES0908]
- NWO Spinoza award
Ask authors/readers for more resources
Active anti-cancer immune responses depend on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with autologous natural APCs is costly and time-consuming and results in variable outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has attracted significant interest as an alternative. We discuss the characteristics of various types of acellular aAPCs, and their clinical potential in cancer immunotherapy. The size, shape, and ligand mobility of aAPCs and their presentation of different immunological signals can all have significant effects on cytotoxic T cell activation. Novel optimized aAPCs, combining carefully tuned properties, may lead to efficient immunomodulation and improved clinical responses in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available